Publications by authors named "F Dane"
Background/aim: The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was developed to predict survivorship in gastric cancer patients undergoing R0 resection. This study aimed to evaluate the predictive power of this nomogram in the Turkish patient population.
Materials And Methods: Gastric cancer patients over 18 years of age who were admitted to our clinic between 2000 and 2019 and underwent primary curative surgery and R0 resection were included in the study.
Total neoadjuvant therapy (TNT) has emerged as a promising approach for managing locally advanced rectal cancer (LARC), aiming to enhance resectability, increase pathological complete response (pCR), improve treatment compliance, survival, and sphincter preservation. This study compares the clinical outcomes of TNT, with either induction or consolidation chemotherapy, to those of the standard chemoradiotherapy (CRT). In this retrospective multi-institutional study, patients with stage II-III LARC who underwent CRT or TNT from seven oncology centers between 2021 and 2024 were retrospectively analyzed.
View Article and Find Full Text PDFBased on the CheckMate 649 trial, nivolumab plus chemotherapy is the recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma. This nationwide, multicenter, retrospective study evaluated the real-world effectiveness of this regimen in Turkish patients and identified subgroups that may experience superior outcomes. Conducted across 16 oncology centers in Turkey, this study retrospectively reviewed the clinical charts of adult patients diagnosed with HER2-negative unresectable advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma from 2016 to 2023.
View Article and Find Full Text PDFArticle Synopsis
- Colorectal cancer is a major global health issue, and in Turkey, a study was conducted to assess the effectiveness of second-line treatments for patients with RAS wild-type metastatic colorectal cancer.
- The research involved a retrospective analysis of 588 patient records from 28 centers, categorizing them by the type of biological treatments received: anti-EGFR and anti-VEGF.
- Results showed no significant differences in overall survival or progression-free survival among the different treatment groups, indicating similar effectiveness of the biological agents in second-line treatments.